Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Recently, a new therapy involving an extracorporal activation of orally administered 8-methoxypsoralen (8-MOP), photosensitizing furocoumarin, is established for the treatment of different skin diseases, extracorporeal photopheresis (ECP). The pharmacokinetic profile of 8-MOP has been pursued as part of a clinical study which should assess the efficacy of ECP in patients with progressive systemic sclerosis and cutaneous T-cell lymphoma. The enormous intra-individual variations proofed for plasma as well as buffy coat concentration are unfavourable for oral 8-MOP therapy. Therefore, the introduction of liquid 8-MOP formulation that allows the direct administration of the drug in to the treatment bag of the ECP device is challenging.
Institute of Clinical Pharmacology, Friedrich Schiller University, Jena, Germany.
A
A
Balogh
U
U
Merkel
A
A
Looks
R
R
Vollandt
U
U
Wollina
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D005260:Female; D006801:Humans; D007937:Leukapheresis; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008730:Methoxsalen / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy; D017893:Photopheresis / Q000379:methods*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000097:blood / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy*
D017319:Photosensitizing Agents; D008730:Methoxsalen